Skip to main content

Verrica Pharmaceuticals Inc.

For the period ended Dec 31, 2025. Filed Mar 11, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 11, 2026

VRCA$3.59+12.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

Page
PART I
Item 1.Business4
Item 1A.Risk Factors26
Item 1B.Unresolved Staff Comments68
Item 1C.Cybersecurity68
Item 2.Properties69
Item 3.Legal Proceedings69
Item 4.Mine Safety Disclosures70
PART II
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities71
Item 6.Reserved71
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations72
Item 7A.Quantitative and Qualitative Disclosures About Market Risk84
Item 8.Financial Statements and Supplementary Data85
Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure113
Item 9A.Controls and Procedures113
Item 9B.Other Information113
Item 9CDisclosure Regarding Foreign Jurisdictions that Prevent Inspections114
PART III
Item 10.Directors, Executive Officers and Corporate Governance114
Item 11.Executive Compensation114
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters114
Item 13.Certain Relationships and Related Transactions, and Director Independence114
Item 14.Principal Accountant Fees and Services114
PART IV
Item 15.Exhibits and Financial Statement Schedules115
Signatures119
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.